

=> b reg
 FILE 'REGISTRY' ENTERED AT 15:18:03 ON 16 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2008 HIGHEST RN 1061881-29-5
 DICTIONARY FILE UPDATES: 15 OCT 2008 HIGHEST RN 1061881-29-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l10
 L8 STR



REP G1=(0-2) C
 VAR G2=NH2/6/9
 VAR G3=O/S
 REP G4=(0-1) C
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E6 C AT 1

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
 L10 764 SEA FILE=REGISTRY SSS FUL L8

100.0% PROCESSED 35689 ITERATIONS 764 ANSWERS
 SEARCH TIME: 00.00.01

=> b hcap
 FILE 'HCAPLUS' ENTERED AT 15:18:10 ON 16 OCT 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 the American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2008 VOL 149 ISS 16
FILE LAST UPDATED: 15 Oct 2008 (20081015/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitrn l15 tot

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
 RN 2005:540575 HCAPLUS
 DN 143:78210
 TI Preparation of piperazine compounds having α -amino acid moiety as
 DPP-IV inhibitors
 IN Akahoshi, Fumihiko; Hayashi, Yoshiharu
 PA Mitsubishi Pharma Corporation, Japan
 SO PCT Int. Appl., 58 pp.
 CODEN: PFXK02
 DT Patent
 LA Japanese
 FAN.CNT 1

PI	WO-----2005056541	KIND	DATE	APPLICATION NO.	DATE
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		20050623	2004WO-JP0018479	20041210
	CA-----2548918	A1	20050623	2004CA-002548918	20041210
	EP-----1695969	A1	20060830	2004EP-000820297	20041210
	R: AT, BE, BG, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN-----1890228	A	20070103	2004CN-080036728	20041210
	US-20070049619	A1	20070301	2006US-000582602	20060630
PRAI	2003JP-000413846	A	20031211		
	2004WO-JP0018479	W	20041210		
OS	MARPAT 143:78210				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compts. I [R1 = H, halo, etc.; R2 = H, halo, etc.; X = CHR3, etc.; R3 = NR7R8, etc.; R7, R8 = H, alkyl, etc.; Y = CR5R6, etc.; R5, R6 = H, halo, etc.; Z = H, CN; m, n = 0-2 such as m + n = 1-3; p = 1-3] were prepared. For example, reductive amination of compound II, e.g., prepared from 4-hydroxy-L-phenylglycine in 3 steps, followed by treatment with trifluoroacetic acid afforded compound III. In serum DPP-IV inhibition assays, the IC50 value of compound III was 1.6 nM. Comps. I are claimed useful for the treatment of diabetes, obesity, etc.

II 855298-68-9P 855298-69-OP 855298-70-3P
 855298-71-4P 855298-72-5P 855298-73-6P
 855298-74-7P 855298-75-8P 855298-76-9P
 855298-77-0P 855298-78-1P 855298-79-2P
 855298-80-5P 855298-81-6P 855298-82-7P
 855298-83-8P 855298-84-9P 855298-85-0P
 855298-86-1P 855298-87-2P 855298-88-3P
 855298-89-4P 855298-90-7P 855298-91-8P
 855298-92-9P 855720-51-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperazine compts. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)

II 855299-01-3P 855299-03-5P 855299-06-8P
 855299-07-9P 855299-13-7P 855299-17-1P
 855299-18-2P 855299-20-6P 855299-21-7P
 855720-71-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of piperazine compts. having α -amino acid moiety as

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 DPP-IV inhibitors for treatment of diabetes and obesity)
 IT 855298-68-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperazine compts. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)
 RN 855298-68-9 HCAPLUS
 CN 3-Pyridinecarbonitrile, 6-[4-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 124 tot

L24 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON SIN
 AN 2003:5484 HCAPLUS
 DN 138:73524
 TI Preparation of hydroxycyclohexyl glycine pyrrolinamide and related compounds
 IN Wierzbicki, Michel; Fourques, Jean-Marie; Levens, Nigel; Hussson-Robert, Bernadette; Nosjean, Olivier; Boulanger, Michelle
 PA Fr.
 SO U.S. Pat. Appl. Publ., 16 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CMI 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-20030004138	A1	20030102	2002US-000173993	20020618 <--
US-----6593312	B2	20030715		
FR-----2826003	A1	20021220	2001FR-000007934	20010618 <--
FR-----2826003	B1	20030815		
NO-2002002891	A	20021219	2002NO-000002891	20020617 <--
NO-----322155	B1	20060821		
EP-----1270562	A2	20030102	2002EP-000291501	20020617 <--
EP-----1270562	A3	20030507		
EP-----1270562	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AJ, TR				
NZ-----519610	A	20030530	2002NZ-000519610	20020617 <--
AT-----277027	T	20041015	2002AT-000291501	20020617
PT-----1270562	T	20041130	2002PT-000291501	20020617
MX-2002PA05997	A	20050217	2002MX-PA0005997	20020617
ES-----2229063	T3	20050416	2002ES-000291501	20020617
CA-----2389858	A1	20021218	2002CA-002389858	20020618 <--
CA-----2389858	C	20070828		
AU-2002048822	A	20021219	2002AU-000048822	20020618 <--
AU-----781822	B2	20050616		
JP-2003012642	A	20030115	2002JP-000176547	20020618 <--
CN-----1392137	A	20030122	2002CN-000121390	20020618 <--
HU-2002002011	A2	20030128	2002HU-000002011	20020618 <--
HU-2002002011	A3	20050728		
ZA-2002004865	A	20030220	2002ZA-000004865	20020618 <--
BR-2002002313	A	20030429	2002BR-000002313	20020618 <--
SK-----285989	B6	20080107	2002SK-000008077	20020618
HK-----1050196	A1	20050522	2003HK-000102394	20030403
PRAI 2001FR-000007934	A	20010618		
OS MARPAT 138:73524				
AB Amides R1OCRR2CRR3CN (NRR4)CONRR5 (R2 forms a saturated carbon ring which may be substituted by one or more alkyl groups; R1, R4 = H or acyl; R2-R6 = H or alkyl; or NRR5 = heterocyclyl) or their stereoisomers and salts were prepared for the treatment of glucose intolerance or disorders associated with hyperglycemia. Thus, (1R,2S,1'S)-2-[(1'-amino-2'-oxo-2'-(1-pyrrolidinyl)ethyl)cyclohexanol was prepared by reaction of [(diphenylmethylene)amino]acetoneitrile with cyclohexene oxide, followed by acidic hydrolysis and reaction with pyrrolidine. The racemic product was separated by chiral HPLC and the enantiomers isolated as fumarates.				
IT 479679-35-1P 479679-36-2P 479679-37-3P				
479679-38-4P 479679-39-5P				
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of hydroxycyclohexyl glycine pyrrolinamide and related compds. for treatment of hyperglycemia)				
RN 479679-35-1 HCAPLUS				
CN Thiazolidine, 3-[(2S)-amino[(1R,2S)-2-hydroxycyclohexyl]acetyl]-, rel-, (2R)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)				
CM 1				
CRN 479679-34-0				
CMF C11 H20 N2 O2 S				
Relative stereochemistry.				


L24 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 479679-36-2 HCAPLUS

CN Ethanone, 2-amino-2-[(1S,2R)-2-hydroxycyclohexyl]-1-(3-thiazolidinyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 479679-37-3 HCAPLUS

CN Thiazolidine, 3-[(2R)-amino[(1S,2R)-2-hydroxycyclohexyl]acetyl]-, (2R)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 479679-36-2
CMF C11 H20 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.

L24 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON SIN (Continued)



RN 479679-38-4 HCAPLUS
 CN Ethanone, 2-amino-2-[(1R,2S)-2-hydroxycyclohexyl]-1-(3-thiazolidinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 479679-39-5 HCAPLUS
 CN Thiazolidine, 3-[(2S)-amino[(1R,2S)-2-hydroxycyclohexyl]acetyl]-, (2R)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 479679-38-4
CMF C11 H20 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS ON SIN

AN 2002:754206 HCAPLUS
 DN 137:273215
 TI Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
 IN Ashton, Wallace T.; Caldwell, Charles G.; Ok, Hyun; Parmee, Emma R.; Weber, Ann E.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CMI 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO-2002076450	A1	20021003	2002WO-US00008931	20020322 <--
W: AB, AG, AL, AM, AT, AU, AZ, BA, BG, BK, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, ME, SD, SL, SE, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2441092	A1	20021003	2002CA-002441092	20020322 <--
AU-2002306823	A1	20021008	2002AU-000306823	20020322 <--
NO-2002306823	B2	20060511		
EP-----1385508	A1	20040204	2002EP-000753819	20020322
EP-----1385508	B1	20080521		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP-2004525929	T	20040826	2002JP-000574965	20020322
AT-----395912	T	20080615	2002AT-000753819	20020322
US-20040106656	A1	20040603	2003US-000472771	20030924
US-----7026316	B2	20060411		
PRAI 2001US-00278931P	P	20010327		
2002WO-US00008931	W	20020322		
AB The present invention is directed to compds. which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compds. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.				
IT 463348-57-4P 463348-58-5P 463348-59-6P				
463348-60-9P 463348-61-0P 463348-62-1P				
463348-63-2P 463348-64-3P 463348-66-5P				
463348-68-7P 463348-69-8P 463348-70-1P				
463348-71-2P 463348-72-3P 463348-73-4P				
463348-74-5P 463348-76-6P 463348-76-7P				
463348-77-8P 463348-78-9P 463348-79-0P				
463348-80-3P 463348-81-4P 463348-82-5P				
463348-83-6P 463348-84-7P 463348-85-8P				
463348-86-9P 463348-87-0P 463348-88-1P				
463348-89-2P 463348-90-5P 463348-91-6P				
463348-92-7P 463348-93-8P 463348-94-9P				
463348-95-0P 463348-96-1P 463348-97-2P				
463348-98-3P 463348-99-4P 463349-00-0P				
463349-01-1P 463349-02-2P 463349-03-3P				
463349-05-5P 463349-06-6P 463349-08-8P				
463349-10-2P 463349-11-3P 463349-13-5P				
463349-14-6P 463349-15-7P 463349-16-8P				
463349-17-9P 463349-18-0P 463349-19-1P				
463349-20-4P 463349-21-5P 463349-22-6P				
463349-23-7P 463349-24-8P 463349-25-9P				
463349-26-0P 463349-27-1P 463349-28-2P				
463349-29-3P 463349-30-4P 463349-31-7P				
463349-34-0P 463349-35-1P 463349-36-2P				
463349-37-3P 463349-38-4P 463349-39-5P				
463349-40-6P 463349-41-7P 463349-42-0P				
463349-43-1P 463349-44-2P 463349-45-3P				
463349-46-4P 463349-47-5P 463349-48-6P				
463349-49-7P 463349-50-8P 463349-51-9P				
463349-52-0P 463349-53-1P 463349-54-2P				
463349-55-3P 463349-56-4P 463349-57-5P				
463349-58-6P 463349-59-7P 463349-60-8P				
463349-61-9P 463349-62-0P 463349-63-1P				
463349-64-2P 463349-65-3P 463349-66-4P				
463349-67-5P 463349-68-6P 463349-69-7P				
463349-70-8P 463349-71-9P 463349-72-0P				
463349-73-1P 463349-74-2P 463349-75-3P				
463349-76-4P 463349-77-5P 463349-78-6P				
463349-79-7P 463349-80-8P 463349-81-9P				
463349-82-0P 463349-83-1P 463349-84-2P				
463349-85-3P 463349-86-4P 463349-87-5P				
463349-88-6P 463349-89-7P 463349-90-8P				
463349-91-9P 463349-92-0P 463349-93-1P				
463349-94-2P 463349-95-3P 463349-96-4P				
463349-97-5P 463349-98-6P 463349-99-7P				
463349-100-8P 463349-101-9P 463349-102-0P				
463349-103-1P 463349-104-2P 463349-105-3P				
463349-106-4P 463349-107-5P 463349-108-6P				
463349-109-7P 463349-110				


L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)
 RL: PAC (Pharmacological activity); PP: (Properties); SPM (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes)
 RN 463348-57-4 HCAPLUS
 CN Benzenesulfonamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-iodo- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-58-5 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-hexyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-59-6 HCAPLUS
 CN Ethanone, 2-amino-2-(trans-4-hydroxycyclohexyl)-1-(3-thiazolidinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 463348-60-9 HCAPLUS
 CN Carbamic acid, [4-(trifluoromethoxy)phenyl]-, trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl ester (3C7) (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463348-61-0 HCAPLUS
 CN Ethanone, 2-amino-2-(trans-4-methoxycyclohexyl)-1-(3-thiazolidinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-62-1 HCAPLUS
 CN Methanesulfonamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-63-2 HCAPLUS
 CN 2-Naphthalenesulfonamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 463348-64-3 HCAPLUS
 CN Benzenesulfonamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-(trifluoromethoxy)- (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463348-66-5 HCAPLUS
 CN Benzenesulfonamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2,4,6-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-68-7 HCAPLUS
 CN Acetamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-69-8 HCAPLUS
 CN Benzenesulfonamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 463348-70-1 HCAPLUS
 CN Benamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-3,4-difluoro- (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463348-71-2 HCAPLUS
 CN Benamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-72-3 HCAPLUS
 CN Benamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2-fluoro-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-73-4 HCAPLUS
 CN Benamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2-fluoro-4-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 463348-74-5 HCAPLUS
 CN Benamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2,5-bis(trifluoromethyl)- (CA INDEX NAME)


L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

Absolute stereochemistry.




RN 463348-75-6 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-76-7 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-77-8 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-fluoro-2-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.


L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

Absolute stereochemistry.




RN 463348-82-5 HCAPLUS
 CN 1-Naphthalenecarboxamide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-83-6 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-3,4-dimethoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-84-7 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 463348-85-8 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-3,5-bis(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463348-78-9 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-79-0 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-80-3 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2,5-difluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 463348-81-4 HCAPLUS
 CN 2-Naphthalenecarboxamide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)


L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

Absolute stereochemistry.




RN 463348-86-9 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2,6-dichloro- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-87-0 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-3,4-dichloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-88-1 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2,4-dichloro- (CA INDEX NAME)


Absolute stereochemistry.



RN 463348-89-2 HCAPLUS
 CN Benzanide, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-methyl- (CA INDEX NAME)


L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 463348-90-5 HCAPLUS
CN Benzamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-91-6 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 463348-92-7 HCAPLUS
CN 1H-Indole-3-carboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)


Absolute stereochemistry.



L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 463348-97-2 HCAPLUS
CN 4-Pyridinecarboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-98-3 HCAPLUS
CN 2-Furancarboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-99-4 HCAPLUS
CN Benzanide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-(dimethylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-00-0 HCAPLUS
CN 5-Isoxazolecarboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-01-1 HCAPLUS
CN Benzenacetamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-4-(trifluoromethoxy)- (CA INDEX NAME)

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 463348-93-8 HCAPLUS
CN 4-Thiazolecarboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-94-9 HCAPLUS
CN 2-Pyridinecarboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-95-0 HCAPLUS
CN Benzanide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-2-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 463348-96-1 HCAPLUS
CN 3-Pyridinecarboxamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.




RN 463349-02-2 HCAPLUS
CN Benzenepropanamide, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-3-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-03-3 HCAPLUS
CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-05-5 HCAPLUS
CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, [4-(1-methylethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463349-06-6 HCAPLUS
CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, (3,4-dichlorophenyl)methyl ester (9CI) (CA INDEX NAME)


L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

Absolute stereochemistry.




RN 463349-08-8 HCAPLUS
 CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, 1-naphthalenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-10-2 HCAPLUS
 CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, 2-naphthalenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-11-3 HCAPLUS
 CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, [3-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)

Absolute stereochemistry.




RN 463349-17-9 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(1,1'-biphenyl)-2-yl- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-18-0 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(1,1'-biphenyl)-4-yl- (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-19-1 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(4-phenoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 463349-20-4 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-13-5 HCAPLUS
 CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, (4-fluorophenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-14-6 HCAPLUS
 CN Carbamic acid, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-, 5-isoxazolymethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-15-7 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-16-8 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(4-(trifluoromethoxy)phenyl)- (CA INDEX NAME)

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-21-5 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-22-6 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-23-7 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(4-iodophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 463349-24-8 HCAPLUS
 CN Urea, N-[trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]-N'-(4-nitrophenyl)- (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-25-9 HCAPLUS
 CN Urea, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-N'-(3,4-dichlorophenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-26-0 HCAPLUS
 CN Urea, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-N'-(3-cyanophenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-27-1 HCAPLUS
 CN Urea, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-N'-(3,4-difluorophenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-34-0 HCAPLUS
 CN Benzamide, N-[(cis-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-2,3-difluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-35-1 HCAPLUS
 CN Carbamic acid, [(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-36-2 HCAPLUS
 CN Carbamic acid, [(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-37-3 HCAPLUS
 CN Carbamic acid, [(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)


RN 463349-28-2 HCAPLUS
 CN Urea, N-[(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-N'-(3-(trifluoromethyl)phenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-29-3 HCAPLUS
 CN Benzenesulfonamide, N-[(cis-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-4-iodo- (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-30-6 HCAPLUS
 CN 2-Naphthalenesulfonamide, N-[(cis-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-4-iodo- (CA INDEX NAME)


Absolute stereochemistry.



RN 463349-31-7 HCAPLUS
 CN Benzenesulfonamide, N-[(cis-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-4-(trifluoromethoxy)- (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-38-4 HCAPLUS
 CN Carbamic acid, (4-phenoxyphenyl)-, trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463349-39-5 HCAPLUS
 CN Carbamic acid, (3-fluorophenyl)-, trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-40-8 HCAPLUS
 CN Carbamic acid, (4-methoxyphenyl)-, trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463349-41-9 HCAPLUS
 CN Carbamic acid, (4-iodophenyl)-, trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-42-0 HCAPLUS
 CN Carbamic acid, (4-iodophenyl)-, trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-43-1 HCAPLUS
 CN Carbamic acid, (3,4-dichlorophenyl)-, trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463349-44-2 HCAPLUS
 CN Carbamic acid, [1,1'-biphenyl]-4-yl-, [cis-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-48-6 HCAPLUS
 CN Carbamic acid, (4-fluorophenyl)-, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-49-7 HCAPLUS
 CN Carbamic acid, (4-methoxyphenyl)-, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 464916-52-7 HCAPLUS
 CN Ethanone, 2-amino-2-[4-(hydroxymethyl)cyclohexyl]-1-(3-thiazolidinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)




RN 463349-45-3 HCAPLUS
 CN Carbamic acid, (4-iodophenyl)-, [cis-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 463349-46-4 HCAPLUS
 CN Carbamic acid, (4-iodophenyl)-, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463349-47-5 HCAPLUS
 CN Carbamic acid, (3-methoxyphenyl)-, [trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on SIN (Continued)



RN 464916-53-8 HCAPLUS
 CN Carbamic acid, [1,1'-biphenyl]-4-yl-, [4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 15:18:53 ON 16 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 15:18:53 ON 16 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:18:53 ON 16 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l25 tot
```

L25 ANSWER 1 OF 2 USPATFULL on STN
 AN 2007:11376 USPATFULL
 TI Image forming apparatus and image forming method
 IN Shishido, Makoto, Osaka, JAPAN
 OKawa, Shino, Osaka, JAPAN
 PI US-20070098442 Al 20070503
 AI 2006US-000582602 Al 20061018 (11)
 PRAI 2005JP-000316760 20051031
 DT Utility
 FS APPLICATION
 LREP Arthur G. Schaier, Carmody & Torrance LLP, 50 Leavenworth Street, P.O.
 Box 1110, Waterbury, CT, 06721-1110, US
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN 9 Drawing Page(s)
 LN.CNT 882

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention provides an image forming apparatus which can, by uniformly leveling the particles which are non-uniformly adhered to the surface of the photoconductor by using a leveling means having a predetermined shape, and can maintain the excellent image characteristics for a long period even when a contact charging method is adopted as a charging means and an image forming method which uses the image forming apparatus. In an image forming apparatus which sequentially arranges a charging means, a developing means, a transferring means and a charge eliminating means around an electrophotographic photoconductor, the charging means is constituted of a contact-type charging means, and a leveling means which levels particles on a surface of the electrophotographic photoconductor is arranged between the transferring means and the charge eliminating means.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

II 855298-68-9P 855298-69-OP 855298-70-3P
 855298-71-4P 855298-72-5P 855298-73-6P
 855298-74-7P 855298-75-8P 855298-76-9P
 855298-77-OP 855298-78-1P 855298-79-2P
 855298-80-5P 855298-81-6P 855298-82-7P
 855298-83-8P 855298-84-9P 855298-85-OP
 855298-86-1P 855298-87-2P 855298-88-3P
 855298-89-4P 855298-90-7P 855298-91-8P
 855298-92-9P 855720-51-3P
 (preparation of piperazine compds. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)
 II 855299-01-3P 855299-03-5P 855299-06-8P
 855299-07-9P 855299-13-7P 855299-17-1P
 855299-18-2P 855299-20-6P 855299-21-7P
 855720-71-7P
 (preparation of piperazine compds. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)
 II 855298-68-9P
 (preparation of piperazine compds. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)
 RN 855298-68-9 USPATFULL
 CN 3-Pyridinecarbonitrile, 6-[4-(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

L25 ANSWER 1 OF 2 USPATFULL on STN (Continued)



L25 ANSWER 2 OF 2 USPATFULL on STN
 AN 2007:56673 USPATFULL
 TI Alpha-amino acid derivatives and use thereof as medicines
 IN Akahoshi, Fumihiko, Chuo-ku, JAPAN
 Hayashi, Yoshiharu, Chuo-ku, JAPAN
 PA Mitsubishi Pharma Corporation, Osaka-shi, JAPAN, 541-0046 (non-U.S. corporation)
 PI US-20070049619 Al 20070301
 AI 2004US-000582602 Al 20041210 (10)
 2004WO-JP0018479 20041210
 PRAI 2003JP-000413846 20031211
 DT Utility
 FS APPLICATION
 LREP LEYDIG VOIT & MAYER, LTD, TWO PRUDENTIAL PLAZA, SUITE 4900, 180 NORTH
 STEITSON AVENUE, CHICAGO, IL, 60601-6731, US
 CLMN Number of Claims: 14
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1780


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds represented by the α -amino acid derivative or a pharmaceutically acceptable salt thereof of the present invention have a therapeutic effect due to a DPP-IV inhibitory action and useful as pharmaceutical agents for the treatment and/or prophylaxis of diseases relating to a DPP-IV inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

II 855298-68-9P 855298-69-OP 855298-70-3P
 855298-71-4P 855298-72-5P 855298-73-6P
 855298-74-7P 855298-75-8P 855298-76-9P
 855298-77-OP 855298-78-1P 855298-79-2P
 855298-80-5P 855298-81-6P 855298-82-7P
 855298-83-8P 855298-84-9P 855298-85-OP
 855298-86-1P 855298-87-2P 855298-88-3P
 855298-89-4P 855298-90-7P 855298-91-8P
 855298-92-9P 855720-51-3P
 (preparation of piperazine compds. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)
 II 855299-01-3P 855299-03-5P 855299-06-8P
 855299-07-9P 855299-13-7P 855299-17-1P
 855299-18-2P 855299-20-6P 855299-21-7P
 855720-71-7P
 (preparation of piperazine compds. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)
 II 855298-68-9P
 (preparation of piperazine compds. having α -amino acid moiety as DPP-IV inhibitors for treatment of diabetes and obesity)
 RN 855298-68-9 USPATFULL
 CN 3-Pyridinecarbonitrile, 6-[4-(trans-4-[(1S)-1-amino-2-oxo-2-(3-thiazolidinyl)ethyl]cyclohexyl)-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 13:47:30 ON 16 OCT 2008)

FILE 'HCAPLUS' ENTERED AT 13:47:40 ON 16 OCT 2008

L1 1 US20070049619 /PN

FILE 'REGISTRY' ENTERED AT 13:47:48 ON 16 OCT 2008

FILE 'HCAPLUS' ENTERED AT 13:47:49 ON 16 OCT 2008

L2 TRA L1 1- RN : 82 TERMS

FILE 'REGISTRY' ENTERED AT 13:47:49 ON 16 OCT 2008

L3 82 SEA L2

L4 68 L3 AND NCSC2/ES

L5 67 L4 AND C6/ES

L6 STR

L7 9 L6

L8 STR L6

L9 35 L8

L10 764 L8 FULL

SAV TEM J602C1A/A L10

L11 36 L10 AND L3

L12 728 L10 NOT L11

FILE 'HCAOLD' ENTERED AT 14:04:35 ON 16 OCT 2008

L13 0 L11

L14 0 L12

FILE 'HCAPLUS' ENTERED AT 14:04:43 ON 16 OCT 2008

L15 1 L11

L16 96 L12

L17 74 L16 AND (PD<=20041210 OR AD<=20041210 OR PRD<=20041210)

L18 62 L16 AND PD<=20031210

L19 12 L17 NOT L18

SEL HIT RN

FILE 'REGISTRY' ENTERED AT 14:06:07 ON 16 OCT 2008

L20 89 E1-89

L21 232 E90-321

L22 8 L21 AND (C12H22N2O2S OR C11H20N2O2S)

FILE 'HCAPLUS' ENTERED AT 15:11:13 ON 16 OCT 2008

L23 2 L22

L24 2 L23 AND L18

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 15:11:46 ON 16 OCT 2008

L25 2 L11

=>